Kwality Pharmaceuticals Reports 39.8% YoY Revenue Growth in Q1 FY26, Eyes X500 Crore Revenue Target

Kwality Pharmaceuticals Ltd ('KPL') reported a strong start to FY26 with consolidated revenue rising 39.8% YoY to X111.8 crore in Q1. This growth was driven primarily by increased sales of registered products across key international markets. EBITDA grew 39% YoY to X24.6 crore, and net profit rose sharply by 43% to X11.9 crore. The company successfully completed a regulatory audit in Zimbabwe and participated in the Pharma Expo in Kenya. It received multiple new product registrations and is preparing for the EU-GMP audit for its general and beta-lactam manufacturing facilities in October. Kwality Pharma is focusing on building a robust international regulatory footprint, driving margin-accretive growth, and investing in differentiated, high-barrier products for sustained value creation.